The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma

Jin, Li; Gu, Bing; Meng, Qinggang; Yan, Zhiqiang; Gao, Huile; Chen, Xishan; Yang, Xiangkun; Lu, Weiyue

doi:10.1088/0957-4484/22/43/435101

Cited by 52 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This includes carbohydrates, folic acid, as well as synthetic small molecules. There are a range of cell-surface receptors targeted here as well, with a few studies focusing on brain tumor [21, 22] and other cancer cell lines [23]. …”

Section: Targeting With Small Moleculesmentioning

confidence: 99%

The Smart Targeting of Nanoparticles

Friedman¹,

Claypool²,

Liu³

2013

CPD

306

183

View full text Add to dashboard Cite

One major challenge in nanomedicine is how to selectively deliver nanoparticles to diseased tissues. Nanoparticle delivery system requires targeting for specific delivery to pathogenic sites when enhanced permeability and retention (EPR) is not suitable or inefficient. Functionalizing nanoparticles is a widely-used technique that allows for conjugation with targeting ligands, which possess inherent ability to direct selective binding to cell types or states and, therefore, confer “smartness” to nanoparticles. This review illustrates methods of ligand-nanoparticle functionalization, provides a cross-section of various ligand classes, including small molecules, peptides, antibodies, engineered proteins, or nucleic acid aptamers, and discusses some unconventional approaches currently under investigation.

show abstract

Section: Targeting With Small Moleculesmentioning

confidence: 99%

The Smart Targeting of Nanoparticles

Friedman¹,

Claypool²,

Liu³

2013

CPD

306

183

View full text Add to dashboard Cite

show abstract

“…Chemical engineering of PEI by addition of functional groups such as poly-ethileneglycol (PEG) or beta-cyclodextrin has proven sufficient to improve PEI permanence in circulation and in the tumor stroma [186]. PEI polymers modified by addition of myristic acid were able to cross the blood brain barrier, delivering a TRAIL-coding plasmid to intracranially implanted gliomas and increasing survival in tumor-bearing mice [187]. Similarly, PEGylated PEI was re-targeted towards glioma cells by chemical addition of an RGD-containing peptide [188].…”

Section: Nanotechnology-based Gene Therapy Of Gbmmentioning

confidence: 99%

Strategies in Gene Therapy for Glioblastoma

Kwiatkowska

Nandhu

Behera

et al. 2013

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive form of brain cancer, with a dismal prognosis and extremely low percentage of survivors. Novel therapies are in dire need to improve the clinical management of these tumors and extend patient survival. Genetic therapies for GBM have been postulated and attempted for the past twenty years, with variable degrees of success in pre-clinical models and clinical trials. Here we review the most common approaches to treat GBM by gene therapy, including strategies to deliver tumor-suppressor genes, suicide genes, immunomodulatory cytokines to improve immune response, and conditionally-replicating oncolytic viruses. The review focuses on the strategies used for gene delivery, including the most common and widely used vehicles (i.e., replicating and non-replicating viruses) as well as novel therapeutic approaches such as stem cell-mediated therapy and nanotechnologies used for gene delivery. We present an overview of these strategies, their targets, different advantages, and challenges for success. Finally, we discuss the potential of gene therapy-based strategies to effectively attack such a complex genetic target as GBM, alone or in combination with conventional therapy.

show abstract

“…These nanoparticles can deliver pORFhTRAIL therapeutics, which are plasmids with a tumor necrosis factor-related apoptosis-inducing ligand. Uptake is enhanced further by associating it with different functional groups, like myristic acid, to significantly increase in vivo median survival times from 22 to 28 days in mice with intracranial U87 glioblastoma [34]. When modified with PEG-RGD sequences, results show an increase in survival from 19 to 23.5 days in the same model mice [35].…”

Section: Polyethylenimine (Pei)mentioning

confidence: 99%

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Ung

Yang

2015

J Neurooncol

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new treatment strategies are needed to improve overall survival. Immunotherapy has emerged as a potential treatment, but still possesses certain limitations to have a substantial clinical effect. In addition, nanotechnology has emerged as potent treatment effectors that have been shown to augment the effects of therapies including chemotherapy, gene therapy, and more. Nanoparticles possess a novel approach due to the myriad of functional groups that can create targeted treatments, though further optimization is still required. In this review, the authors will present the current uses and abilities of nanotechnology and its implication for use with immunotherapy in the treatment of GBM.

show abstract

The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma

Cited by 52 publications

References 40 publications

The Smart Targeting of Nanoparticles

The Smart Targeting of Nanoparticles

Strategies in Gene Therapy for Glioblastoma

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Contact Info

Product

Resources

About